Becton, Dickinson and Company (NYSE:BDX) Shares Bought by FSB Premier Wealth Management Inc.

FSB Premier Wealth Management Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 19.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,699 shares of the medical instruments supplier’s stock after purchasing an additional 611 shares during the period. FSB Premier Wealth Management Inc.’s holdings in Becton, Dickinson and Company were worth $839,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wesbanco Bank Inc. lifted its stake in shares of Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after buying an additional 48 shares in the last quarter. S.A. Mason LLC increased its stake in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock worth $321,000 after buying an additional 50 shares during the period. Hillsdale Investment Management Inc. lifted its holdings in Becton, Dickinson and Company by 1.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock worth $694,000 after buying an additional 50 shares during the last quarter. Americana Partners LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after buying an additional 52 shares in the last quarter. Finally, Picton Mahoney Asset Management lifted its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. The trade was a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Barclays increased their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $278.29.

Becton, Dickinson and Company Trading Down 0.6 %

Becton, Dickinson and Company stock opened at $227.34 on Monday. The firm’s 50 day moving average price is $231.83 and its two-hundred day moving average price is $231.72. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market cap of $65.28 billion, a price-to-earnings ratio of 37.76, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.